Detalhe da pesquisa
1.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Breast Cancer Res
; 25(1): 103, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37653397
2.
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Ann Oncol
; 30(6): 921-926, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30778520
3.
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Ann Oncol
; 26(12): 2429-36, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26387142
4.
Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA.
J Cancer Res Clin Oncol
; 148(6): 1543-1550, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35396978
5.
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.
ESMO Open
; 6(2): 100086, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743331
6.
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Breast
; 35: 115-121, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28711793